FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
RGNX•FDA halts Regenxbio gene therapy trial
Aug. 24 (Reuters) - Regenxbio RGNX.O said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal MRI scans found abnormalities in five study participants.
